Traws Pharma, Inc. — Form S-1
Filed October 26, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 78/100
What the filing says
On October 23, 2026, Traws Pharma (market cap ~$9.8M) entered a Common Stock Purchase Agreement with Roth Principal Investments, LLC for a committed equity facility of up to $50 million gross proceeds. The company may sell up to 135,135,135 shares (89.79% dilution at current price) at 94% of VWAP, over 36 months, subject to Nasdaq exchange cap and beneficial ownership limits. Company receives no proceeds from resales; timing and amount are solely at company's discretion.
Why this rating
Material financing lifeline ($50M = 510% of current market cap) addresses near-term cash runway but massive dilution (up to 90% of float), pricing discount, and discretionary timing create substantial shareholder risk. Significant but not transformational absent actual drawdown.
Price action (we called it neutral)
before filing · preread $0.35 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.